AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10511608
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment and H. pylori-negative patients
Trial: 10511608
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment and H. pylori-positive patients
Trial: 7381554
Drug: CT assessments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT assessments before initiating radio-chemotherapy and at the completion of each cycle
Trial: 30178187
Drug: Small tidal
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small tidal volume (STV) ventilation (3-5 mL/kg)
Trial: 30178187
Drug: Large tidal
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large tidal volume (LTV) ventilation (6-8 mL/kg)
Trial: 27789115
Drug: Diazepam 5
RxNorm normalized name: diazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 5 mg orally
Trial: 27789115
Drug: Meclizine 25
RxNorm normalized name: meclizine 25 MG
DrugBank: Meclizine (DB00737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meclizine 25 mg orally
Trial: 25393080
Drug: Melatonin/hypothermia group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin/hypothermia group (N=15; received hypothermia and five daily enteral doses of melatonin 10 mg kg(‐1))
Trial: 24412265
Drug: Foot-drop stimulator
RxNorm normalized name: Fungi-Nail Toe and Foot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foot-drop stimulator (FDS; Bioness L300) used for ambulation over 42 weeks after 8 physical therapy sessions
Trial: 17270006
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg (single dose)
Trial: 17270006
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg and esomeprazole 40 mg (single doses)
Trial: 17270006
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg (5 days' dosing)
Trial: 17270006
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg vs. rabeprazole 10 mg (5 days' dosing)
Trial: 15650984
Drug: diclofenac/paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac/paracetamol
Trial: 11786584
Drug: Isotretinoin added
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin added to hormonal therapy (arm 1)
Trial: 11786584
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy alone (arm 2)
Trial: 1099047
Drug: Contingent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Contingent administration of naloxone (N-allylnoroxymorphone) 500-2000 mg daily
Trial: 31828863
Drug: Wheat germ
RxNorm normalized name: Wheat Germ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat germ (WG) supplementation, 20g daily for 12 weeks
Trial: 19543080
Drug: Nifedipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (30 mg/day) upon awakening
Trial: 15286880
Drug: Gatifloxacin IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin IV followed by oral administration
Trial: 15286880
Drug: Ceftriaxone IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone IV alone or in combination with erythromycin IV, followed by clarithromycin PO
Trial: 9437184
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg daily soy isoflavones (45 mg genistein)
Trial: 2825745
Drug: Dipyridamole 150/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole 150/200 mg single doses
Trial: 2825745
Drug: Dipyridamole 150/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole 150/200 mg multiple doses (twice daily for 11 days)
Trial: 2825745
Drug: Dipyridamole (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (various doses)
Trial: 2825745
Drug: Dipyridamole (150/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (150/200 mg)
Trial: 20947492
Drug: Dose-matched therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-matched therapeutic exercise (DMTE)
Trial: 1347857
Drug: CGRP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CGRP infusion at 0.6 micrograms/min for 4 hours, then up to a maximum of 10 days
Trial: 2988107
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g coarse wheat bran
Trial: 2988107
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g placebo bran
Trial: 19054552
Drug: Tasimelteon 20
RxNorm normalized name: tasimelteon 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tasimelteon 20 mg
Trial: 30353049
Drug: Complete Decongestive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete Decongestive Therapy including manual lymphatic drainage (T+MLD)
Trial: 30353049
Drug: Complete Decongestive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete Decongestive Therapy without manual lymphatic drainage (T-MLD)
Trial: 24154667
Drug: Intravenous lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lorazepam (LRZ; 0.01 mg/kg)
Trial: 22198049
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) plus l-carnitine, celecoxib, and antioxidants (arm 1)
Trial: 17385970
Drug: Psychological preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological preparation for surgery
Trial: 17984132
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (1 x 10(6) cells/0.1 mL, n = 9)
Trial: 17984132
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (2 x 10(6) cells/0.1 mL, n = 10)
Trial: 17984132
Drug: Control (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0.1 mL autologous plasma/injection, n = 9)
Trial: 6438683
Drug: Sulpiride (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (800 mg/day)
Trial: 6438683
Drug: Chlorpromazine (CPZ)
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (CPZ) (400 mg/day)
Trial: 31256717
Drug: High medication
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High medication burden
Trial: 31256717
Drug: Intensive vs
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive vs Standard treatment
Trial: 31256717
Drug: Medication burden
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication burden
Trial: 29744647
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow grafting (percutaneous mesenchymal cell injection)
Trial: 27071759
Drug: Duloxetine (55
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (55 mg/day, range 40-60 mg/day)
Trial: 27071759
Drug: Sertraline (146
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (146 mg/day, range 50-200 mg/day)
Trial: 20202239
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with 0.2% betamethasone-hyaluronidase cream twice a day for 8 weeks
Trial: 11821087
Drug: No Hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No Hormone Replacement Therapy
Trial: 7726526
Drug: Cloxacillin 2
RxNorm normalized name: cloxacillin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cloxacillin 2 g every 4 hours and Gentamicin 1.5 mg/kg every 8 hours for 2 weeks (Group A)
Trial: 7726526
Drug: Teicoplanin 10
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin 10 mg/kg/12 hours on days 1-3, 6 mg/kg/12 hours on days 4-7, and 7 mg/kg/24 hours on day 8 (Group B)
Trial: 30268346
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) promethazine
Trial: 30268346
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Ondansetron
Trial: 23819659
Drug: methylprednisolone 80 mg + 5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylprednisolone 80 mg + 5 mL of levobupivacaine without epinephrine + 3 mL of 0.9% saline solution
Trial: 23819659
Drug: methylprednisolone 80 mg + 8 mL
RxNorm normalized name: methylprednisolone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylprednisolone 80 mg + 8 mL of 0.9% saline solution
Trial: 16015691
Drug: Itopride 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itopride 150 mg t.i.d.
Trial: 16015691
Drug: Itopride 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itopride 300 mg t.i.d.
Trial: 6401908
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 to 80 mg 4 times a day)
Trial: 6401908
Drug: Pindolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (5 to 10 mg 2 times a day)
Trial: 29573460
Drug: Poor self-rated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poor self-rated oral health in older age group
Trial: 29573460
Drug: Poor self-rated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poor self-rated oral health in Guarani peoples
Trial: 27114074
Drug: Lenalidomide/dexamethasone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide/dexamethasone plus high-dose chemotherapy and autologous stem cell transplantation followed by lenalidomide maintenance
Trial: 19124377
Drug: Erdosteine 300
RxNorm normalized name: erdosteine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdosteine 300 mg
Trial: 15755632
Drug: OncoVAX therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OncoVAX therapy (active specific immunotherapy using autologous tumor cells with BCG vaccine)
Trial: 15755632
Drug: OncoVAX therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OncoVAX therapy
Trial: 8748726
Drug: Standardized immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized immunotherapy (IT) (Alpare)
Trial: 22201324
Drug: Optimized aspheric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized aspheric treatment zone ablation (OATz)
Trial: 17976843
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) with and without defibrillator back‐up
Trial: 12008991
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (n=54) attended two group nutrition education classes and one individual diet counseling session led by the same dietitian.
Trial: 10321414
Drug: Eprosartan 600
RxNorm normalized name: eprosartan 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan 600 mg once daily
Trial: 8735463
Drug: Dermal exposure
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermal exposure to 86 mg/m3 cis-1,3-DCP for 45 minutes
Trial: 1767904
Drug: Midazolam IV
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam IV solution 10 mg
Trial: 6412612
Drug: alfentanil 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil 0.75 mg
Trial: 6412612
Drug: fentanyl 0.25
RxNorm normalized name: bupivacaine-fentanyl 0.25%-20 mcg/mL-0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fentanyl 0.25 mg
Trial: 29545067
Drug: Natalizumab 300
RxNorm normalized name: natalizumab 300 MG in 15 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natalizumab 300 mg intravenous every 4 weeks for 2 years
Trial: 23203322
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA, 10 mg/d for 10 days per cycle)
Trial: 23203322
Drug: Norethisterone (NET,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethisterone (NET, 15 mg/d for 10 days per cycle)
Trial: 14623537
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (anastrozole + tamoxifen)
Trial: 10928757
Drug: Bacitracin ointment
RxNorm normalized name: Bacitracin Ointment
DrugBank: Bacitracin (DB00626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bacitracin ointment (or erythromycin/gentamicin if resistant to bacitracin) applied to the lid margin
Trial: 3894250
Drug: Acebutolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (100 mg intravenous perfusion over 24 hr or 600 mg orally, followed by 1200 mg/day orally)
Trial: 29148629
Drug: Mouth rinse
RxNorm normalized name: Ulcerease 0.6 % Mouth Rinse
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouth rinse with carbohydrate solution (MRCS)
Trial: 22622138
Drug: Baseline PIIINP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PIIINP levels <0.72 U/mL
Trial: 22622138
Drug: Baseline PIIINP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PIIINP levels >0.72 U/mL
Trial: 20860916
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of mycophenolate mofetil 500 mg (Suprimun®)
Trial: 20860916
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of mycophenolate mofetil 500 mg
Trial: 16687365
Drug: Mecamylamine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecamylamine (6 mg/day)
Trial: 31037806
Drug: Low-volume resistance
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume resistance training (6 months, twice a week)
Trial: 31037806
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (maintained pharmacological treatments)
Trial: 23421600
Drug: Acetyl-L-carnitine (ALC)
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl-L-carnitine (ALC) 3 g/day with riluzole 100 mg/day
Trial: 23421600
Drug: Placebo 3
RxNorm normalized name: placebo 330 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3 g/day with riluzole 100 mg/day
Trial: 9098093
Drug: Oil-based Q10
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil-based Q10 (90 mg/d)
Trial: 9098093
Drug: Granular Q10
RxNorm normalized name: SAXIFRAGA GRANULATA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granular Q10 (90 mg/d)
Trial: 9098093
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Q10 (single dose)
Trial: 8218955
Drug: Transnasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transnasal administration of butorphanol (2 mg)
Trial: 8218955
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of butorphanol (2 mg)
Trial: 8218955
Drug: Buccal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal administration of butorphanol (2 mg)
Trial: 8218955
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of butorphanol (2 mg)
Trial: 3700691
Drug: Cimetidine 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 1,200 mg/d
Trial: 4085354
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg/d
Trial: 28743757
Drug: Erythropoiesis-stimulating agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoiesis-stimulating agent (ESA) treatment
Trial: 22269382
Drug: Screening arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Screening arm (PSA every 4 years, prostate biopsy when PSA ≥3 ng/ml)
Trial: 17513813
Drug: Active specific
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active specific immunotherapy with allogeneic melanoma lysates and low-dose interferon alfa-2b (IFN-alpha-2b) for 2 years
Trial: 17513813
Drug: High-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon alfa-2b for 1 year
Trial: 12243812
Drug: Postoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiation with concomitant and maintenance chemotherapy (96% of patients)
Trial: 8586126
Drug: OKY-046 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKY-046 (400 mg/day)
Trial: 823084
Drug: Butalamine hydrochloride
RxNorm normalized name: butalamine hydrochloride
DrugBank: Butalamine (DB13681)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butalamine hydrochloride (3 X 2 tablets daily)
Trial: 28335837
Drug: Potent P2Y12
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potent P2Y12 inhibitors (prasugrel, ticagrelor, intravenous cangrelor)
Trial: 15143715
Drug: S-adenosy-L-methionine (SAM)
RxNorm normalized name: L-methionine-S,R-sulfoximine
DrugBank: Methionine sulfoximine (DB14103)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosy-L-methionine (SAM)
Trial: 9209184
Drug: Carbohydrate supplementation
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate supplementation (0.75 L carbohydrate beverage, 0.25 L every 15 min during running)
Trial: 9209184
Drug: Placebo (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.75 L placebo beverage, 0.25 L every 15 min during running)
Trial: 8094467
Drug: Taxol (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxol (250 mg/m2 by 24-hour intravenous infusion every 3 weeks)
Trial: 8094467
Drug: Merbarone (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Merbarone (1000 mg/m2 by continuous intravenous infusion daily for 5 days every 3 weeks)
Trial: 8094467
Drug: Piroxantrone (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxantrone (150 mg/m2 by intravenous infusion over 1 hour every 3 weeks)
Trial: 2887097
Drug: Nifedipine (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (in patients already receiving beta blockers)
Trial: 27333620
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone combined with rhTPO
Trial: 27333620
Drug: Single high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high-dose dexamethasone
Trial: 25192026
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Zn/day (experimental group)
Trial: 21283046
Drug: Interrupted sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interrupted sedation protocol (midazolam bolus of 0.1 mg/kg, followed by infusion with daily interruption)
Trial: 21283046
Drug: Continuous sedation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous sedation protocol (midazolam bolus of 0.1 mg/kg, followed by continuous infusion)
Trial: 15972728
Drug: Trimethoprim 300
RxNorm normalized name: trimethoprim 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim 300 mg daily for three days
Trial: 12579169
Drug: Timolol/dorzolamide fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol/dorzolamide fixed combination
Trial: 21780543
Drug: Intracervical dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intracervical dinoprostone 0.5 mg
Trial: 16916334
Drug: Theophylline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (100 mg b.i.d.)
Trial: 12776806
Drug: Test cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test cyclosporine non-SMEDDS formulation
Trial: 12776806
Drug: Cyclopsorine SMEDDS
RxNorm normalized name: Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclopsorine SMEDDS formulation
Trial: 9887161
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (3 g [1200 mg of elemental calcium] daily)